NCT02881879View on ClinicalTrials.gov

Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctivitis Sensitized to House Dust Mites

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Allergic Rhinoconjunctivitis
Interventions
BIOLOGICAL

Allergovac depot DPT/DF (50:50)

Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections

Trial Locations (5)

08916

Hospital Germans Triasl i Pujol, Badalona

Unknown

Hospital de Bellvitge, Barcelona

Hospital de Basurto, Bilbao

Hospital de Valdecilla, Santander

Hospital Universitario de Araba, Vitoria-Gasteiz

All Listed Sponsors
lead

Roxall Medicina España S.A

INDUSTRY

NCT02881879 - Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctivitis Sensitized to House Dust Mites | Biotech Hunter | Biotech Hunter